Hepatobiliary membrane transporters in primary biliary cirrhosis

Takeyama, Yoshifumi; Sakisaka, Shotaro

doi:10.1111/j.1872-034x.2011.00912.x

Cited by 13 publications

(7 citation statements)

References 65 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…191 MRP1 and OST α/β, which are not expressed or expressed at low levels in normal hepatocytes, are upregulated in patients with PBC. 149,190,193,194 Consistent with the literature findings, data from our laboratory indicated that MRP1 protein was expressed in liver tissue from a patient with PBC (Figure 1). Interestingly, our findings suggest that MRP1 was expressed primarily in the inflamed tissues in macrophages around the hepatocytes in PBC.…”

Section: Introductionsupporting

confidence: 89%

“…189 Interestingly, it was reported that these alterations may be related to the adaptation of transporters, and that expression patterns may change from early to late stage PBC. 190,193 In addition to the changes in expression, the localization of MRP2 was altered in PBC stage III. 191 MRP1 and OST α/β, which are not expressed or expressed at low levels in normal hepatocytes, are upregulated in patients with PBC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Liver Disease on Hepatic Transporter Expression and Function

Thakkar

Slizgi

Brouwer

2017

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Liver disease can alter the disposition of xenobiotics and endogenous substances. Regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) recommend, if possible, studying the effect of liver disease on drugs under development to guide specific dose recommendations in these patients. While extensive research has been conducted to characterize the effect of liver disease on drug-metabolizing enzymes, emerging data have implicated that the expression and/or function of hepatobiliary transport proteins also are altered in liver disease. This review summarizes recent developments in the field, which may have implications for understanding altered disposition, safety, and of efficacy of new and existing drugs. A brief review of liver physiology and hepatic transporter localization/function is provided. Then, the expression and function of hepatic transporters in cholestasis, hepatitis C infection, hepatocellular carcinoma (HCC), human immunodeficiency virus (HIV) infection, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and primary biliary cirrhosis (PBC) are reviewed. In the absence of clinical data, nonclinical information in animal models is presented. This review aims to advance the understanding of altered expression and function of hepatic transporters in liver disease and the implications of such changes on drug disposition.

show abstract

Section: Introductionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Effect of Liver Disease on Hepatic Transporter Expression and Function

Thakkar

Slizgi

Brouwer

2017

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

show abstract

“…Bile acids play an important role in regulating the metabolism balance of lipids in vivo (1). They are converted from cholesterol in liver by a series of enzymes, and they maintain a dynamic balance through the uptake and efflux of hepatocellular transporter as well as the enterohepatic circulation (2). Some liver diseases and drug-induced liver injury are often accompanied by obstacles in the synthesis, metabolism and excretion of bile acids, potentially leading to the accumulation of bile acids.…”

Section: Introductionmentioning

confidence: 99%

Effects of rhein on bile acid homeostasis in rats

Xian

Tian

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract：Rhein, the active ingredient of rhubarb, a medicinal and edible plant, is widely used in clinical practice. In this work, we investigated the alterations of 14 bile acids and hepatic transporters after rats were administered rhein for 5 consecutive weeks.There was no obvious injury to the liver and kidney, and there were no significant changes in biochemical indicators. However, 1,000 mg/kg rhein increased the liver total bile acid (TBA) levels, especially taurine-conjugated bile acids (t-CBAs), inhibited the expression of Farnesoid X receptor (FXR) and (bile salt export pump) BSEP mRNA, and upregulated the expression of (cholesterol 7α-hydroxylase) CYP7A1 mRNA. Rhein close to the clinical dose reduced the amounts of TBAs, especially unconjugated bile acids (UCBAs), and elevated the expression of FXR and resistance-associated protein 3 (Mrp3) mRNA. These results denote that rhein is not toxic and is safe to use at a reasonable dose and timing.

show abstract

“…PBC causes functional impairment of bile salt and organic anion efflux. In response, hepatobiliary transporters are expressed to prevent bile acid accumulation in hepatocytes . We previously described that the lack of adaptation to the upregulation of hepatobiliary transporters may be related to PBC progression …”

Section: Introductionmentioning

confidence: 99%

“…In response, hepatobiliary transporters are expressed to prevent bile acid accumulation in hepatocytes. 1 We previously described that the lack of adaptation to the upregulation of hepatobiliary transporters may be related to PBC progression. 2,3 The organic anion transporter peptide 1B3 (OATP1B3; also called OATP8 or solute carrier organic anion transporter family member 1B3 [SLCO1B3]), which is expressed in the basolateral membrane of hepatocytes, is especially important for the transport of agents such as gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA), as well as the uptake of endogenous substances and xenobiotics into the hepatocytes.…”

Section: Introductionmentioning

confidence: 99%

Gadolinium‐ethoxybenzyl‐diethylenetriamine pentaacetic acid‐enhanced magnetic resonance imaging as a useful detection method for advanced primary biliary cirrhosis

Takeyama

Tsuchiya

Kunimoto

et al. 2015

Hepatology Research

Self Cite

View full text Add to dashboard Cite

Aim:In primary biliary cirrhosis (PBC), damaged hepatocytes resulting from chronic cholestasis follow a compensatory mechanism that alters hepatobiliary transporter expression to reduce the accumulation of potentially toxic compounds such as bile acid. Organic anion transporter peptide 1B3 (OATP1B3), which transports agents such as gadolinium-ethoxybenzyldiethylenetriamine pentaacetic acid (Gd-EOB-DTPA), has reduced expression in the late stages of PBC. Therefore, we investigated the use of Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) as a useful detection method for the advanced staging of PBC. Methods: Stage IÀIII PBC (non-liver cirrhosis [LC]-PBC, n = 12),stage IV (LC-PBC, n = 6), and nonÀPBC patients (control group, n = 4) were included in this study. We obtained liver tissue samples by percutaneous liver biopsy. Hepatic OATP1B3 expression was determined immunohistochemically, and OATP1B3 mRNA levels were assessed using real-time reverse transcription polymerase chain reaction. The relative enhancement (RE) in the hepatobiliary phase was calculated using the signal intensity of Gd-EOB-DTPA-enhanced MRI.Results: Immunohistochemistry revealed markedly reduced expression of OATP1B3 in hepatocytes around the central vein in LC-PBC patients. Hepatic OATP1B3 mRNA expression in LC-PBC patients was significantly lower than that in non-LC-PBC patients (P < 0.05). The RE on MRI was significantly decreased in the LC-PBC group (0.33 ± 0.14) compared with the non-LC-PBC (0.91 ± 0.15, P < 0.01) and control (0.92 ± 0.20, P < 0.01) groups.Conclusion: Gd-EOB-DTPA-enhanced MRI may provide a useful detection method for liver disease in patients with LC-PBC.

show abstract

Hepatobiliary membrane transporters in primary biliary cirrhosis

Cited by 13 publications

References 65 publications

Effect of Liver Disease on Hepatic Transporter Expression and Function

Effect of Liver Disease on Hepatic Transporter Expression and Function

Effects of rhein on bile acid homeostasis in rats

Gadolinium‐ethoxybenzyl‐diethylenetriamine pentaacetic acid‐enhanced magnetic resonance imaging as a useful detection method for advanced primary biliary cirrhosis

Contact Info

Product

Resources

About